NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) issued its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company had revenue of $6.06 million for the quarter, compared to analyst estimates of $7.80 million. Cytokinetics had a negative net margin of 378.70% and a negative return on equity of 10,351.99%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Cytokinetics.

Cytokinetics will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 analysts have issued 12-month price objectives for Cytokinetics' shares. Their forecasts range from $16.00 to $30.00. On average, they anticipate Cytokinetics' stock price to reach $22.17 in the next year. This suggests a possible upside of 59.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

Media stories about CYTK stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cytokinetics.

Cytokinetics saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a decline of 9.9% from the January 15th total of 9,400,000 shares. Based on an average daily trading volume, of 913,000 shares, the days-to-cover ratio is currently 9.3 days. Approximately 15.7% of the company's shares are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Nektar Therapeutics (NKTR), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), GW Pharmaceuticals PLC- (GWPH), Alkermes (ALKS), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO), Allakos (ALLK), Myokardia (MYOK), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Deciphera Pharmaceuticals (DCPH) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Geode Capital Management LLC (1.35%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, Credit Suisse AG and Barclays PLC. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $13.94.

Cytokinetics has a market capitalization of $823.28 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]